Effect of Febuxostat and Allopurinol on Patients with Chronic Kidney Disease with Hyperuricemia
Objective:To explore the effect of Febuxostat and Allopurinol on chronic kidney disease(CKD)with hyperuricemia(HUA).Method:A total of 100 patients with CKD and HUA admitted to Wudang Hospital Affiliated to Guizhou Medical University from September 2019 to February 2023 were selected.They were divided into control group and observation group according to random number table method,with 50 cases in each group.The control group was given Allopurinol Tablets,and the observation group was given Febuxostat Tablets.The clinical efficacy,inflammatory factors,renal function before and after treatment and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and myeloperoxidase(MPO)in both groups were reduced,and the levels of TNF-α,IL-6 and MPO in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,blood urea nitrogen(BUN),blood creatinine(Scr),blood uric acid(SUA)and urinary microalbumin were decreased in both groups,and the estimated glomerular filtration rate(eGFR)was increased,BUN,Scr,SUA and urinary microalbumin in observation group were lower than those in control group,and eGFR was higher than that in control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion:Compared with Allopurinol,Febuxostat is more effective in the treatment of CKD patients with HUA,which can better reduce the level of serum inflammatory factors and improve renal function,and the incidence of adverse reactions is lower.
Chronic kidney disease with hyperuricemiaFebuxostatAllopurinolClinical efficacyInflammatory factorsRenal functionAdverse reactions
国家科技期刊平台
NSTL
万方数据
维普
